PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, Norway, 29 August 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA gene therapies, today announces its first half-year 2024 results.
Circio's management will present the results in a live-streamed webcast at 10:00 am CEST to investors, analysts and the press. Click here for access to the live webcast (http://teams.microsoft.com/l/meetup-join/19%3ameeting_N2U2Njg5OTYtYjZjMC00MDBlLThlMjUtZjg4MTQwOTYzMDUy%40thread.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d)
Questions can be submitted by email in advance (to: lubor.gaal@circio.com)and during the presentation.
Reporting material attached to this press release:- Circio first-half year report 2024
- Circio 1H24 webcast presentation
The report and presentation are also available at www.circio.com
***
First half-year 2024 highlights
Corporate- In January, Business Finland approved Circio's application for a waiver of three R&D loans totaling NOK 71.3 million
- In May, launched a financing transaction securing cash runway for 12 months through a rights issue and parallel commitment from Atlas Capital Markets
- Cash burn of NOK 19 million, representing a 68% reduction versus 1H23
- In April, announced technical in vivo proof-of-concept for its proprietary circVec circular RNA platform with >4-month expression durability
- In May, presented two circVec posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting in Baltimore, USA
- In June, announced a new generation circVec 2.2, achieving 2-4-fold higher expression than v2.1 and up to 15x improvement over mRNA expression
- In February, announced that the first patient was dosed in the Georgetown University Phase 2 study, testing TG01 in a triple combination in collaboration with Janssen and BMS
- In March, the Chinese National Medical Products Administration (NMPA) approved the investigational new drug (IND) application of TG01
***